Evidence map›Paper›PMID 33742556›Full record

ArticleESC heart failure2021

Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice.

Marie Pieronne-Deperrois, Alexandre Guéret, Zoubir Djerada, Clément Crochemore, Najah Harouki, Jean-Paul Henry, Anaïs Dumesnil, Marine Larchevêque, Jean-Claude do Rego, Jean-Luc do Rego and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESC heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 3 countries.

Marie Pieronne-DeperroisInserm U1096 ENVI, Rouen Medical School, UNIROUEN, Normandy University, Rouen, France.ORCID 0000-0003-2933-3557
Alexandre GuéretInserm U1096 ENVI, Rouen Medical School, UNIROUEN, Normandy University, Rouen, France.
Zoubir DjeradaPharmacology Department, Reims University Hospital, Reims, France.
Clément CrochemoreEA4651 Toxemac-ABTE, Rouen Medical School, UNIROUEN, Normandy University, Rouen, France.
Najah HaroukiInserm U1096 ENVI, Rouen Medical School, UNIROUEN, Normandy University, Rouen, France.
Jean-Paul HenryInserm U1096 ENVI, Rouen Medical School, UNIROUEN, Normandy University, Rouen, France.
Anaïs DumesnilInserm U1096 ENVI, Rouen Medical School, UNIROUEN, Normandy University, Rouen, France.
Marine LarchevêqueInserm U1096 ENVI, Rouen Medical School, UNIROUEN, Normandy University, Rouen, France.
Jean-Claude do RegoSCAC Behavioral Analysis Platform, Rouen Medical School, UNIROUEN, Normandy University, Rouen, France.
Jean-Luc do RegoSCAC Behavioral Analysis Platform, Rouen Medical School, UNIROUEN, Normandy University, Rouen, France.
Lionel NicolInserm U1096 ENVI, Rouen Medical School, UNIROUEN, Normandy University, Rouen, France.
Vincent RichardInserm U1096 ENVI, Rouen Medical School, UNIROUEN, Normandy University, Rouen, France.
Frédéric JaisserInserm U1138, Cordeliers Institute, Paris-VI University, Paris, France.
Peter KolkhofBayer AG, Wuppertal, Germany.
Paul MulderInserm U1096 ENVI, Rouen Medical School, UNIROUEN, Normandy University, Rouen, France.
Christelle MonteilEA4651 Toxemac-ABTE, Rouen Medical School, UNIROUEN, Normandy University, Rouen, France.
Antoine Ouvrard-PascaudInserm U1096 ENVI, Rouen Medical School, UNIROUEN, Normandy University, Rouen, France.
Inserm · FRNormandie Université · FRBayer (Germany) · DECentre Hospitalier Universitaire de Reims · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsIn post-menopausal women, incidence of heart failure with preserved ejection fraction is higher than in men. Hormonal replacement therapies did not demonstrate benefits. We tested whether the non-steroidal mineralocorticoid receptor antagonist finerenone limits the progression of heart failure in ovariectomized (OVX) mice with metabolic disorders. METHODS AND

resultsOvariectomy was performed in 4-month-old mice, treated or not at 7 months old for 1 month with finerenone (Fine) 1 mg/kg/day. Left ventricular (LV) cardiac and coronary endothelial functions were assessed by echocardiography, catheterization, and myography. Blood pressure was measured by plethysmography. Insulin and glucose tolerance tests were performed. Exercise capacity and spontaneous activity were measured on treadmill and in combined indirect calorimetric cages equipped with voluntary running wheel. OVX mice presented LV diastolic dysfunction without modification of ejection fraction compared with controls (CTL), whereas finerenone improved LV filling pressure (LV end-diastolic pressure, mmHg: CTL 3.48 ± 0.41, OVX 6.17 ± 0.30**, OVX + Fine 3.65 ± 0.55

conclusionsFinerenone improved cardiovascular dysfunction and exercise capacity after ovariectomy-induced LV diastolic dysfunction with preserved ejection fraction.

Indexed as

Exercise ToleranceReceptors, MineralocorticoidAnimalsFemaleMiceMineralocorticoid Receptor AntagonistsNaphthyridinesfinerenoneMineralocorticoid Receptor AntagonistsNaphthyridinesReceptors, MineralocorticoidAldosteroneDiastolic dysfunctionExerciseMenopauseMetabolic syndromeMineralocorticoid receptorOvariectomy

Identifiers

PMID33742556
PMCPMC8120350
OpenAlexW3139423249

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.